RESUMO
Importance: Repeated mass distribution of azithromycin has been shown to reduce childhood mortality by 14% in sub-Saharan Africa. However, the estimated effect varied by location, suggesting that the intervention may not be effective in different geographical areas, time periods, or conditions. Objective: To evaluate the efficacy of twice-yearly azithromycin to reduce mortality in children in the presence of seasonal malaria chemoprevention. Design, Setting, and Participants: This cluster randomized placebo-controlled trial evaluating the efficacy of single-dose azithromycin for prevention of all-cause childhood mortality included 341 communities in the Nouna district in rural northwestern Burkina Faso. Participants were children aged 1 to 59 months living in the study communities. Interventions: Communities were randomized in a 1:1 ratio to receive oral azithromycin or placebo distribution. Children aged 1 to 59 months were offered single-dose treatment twice yearly for 3 years (6 distributions) from August 2019 to February 2023. Main Outcomes and Measures: The primary outcome was all-cause childhood mortality, measured during a twice-yearly enumerative census. Results: A total of 34â¯399 children (mean [SD] age, 25.2 [18] months) in the azithromycin group and 33â¯847 children (mean [SD] age, 25.6 [18] months) in the placebo group were included. A mean (SD) of 90.1% (16.0%) of the censused children received the scheduled study drug in the azithromycin group and 89.8% (17.1%) received the scheduled study drug in the placebo group. In the azithromycin group, 498 deaths were recorded over 60â¯592 person-years (8.2 deaths/1000 person-years). In the placebo group, 588 deaths were recorded over 58â¯547 person-years (10.0 deaths/1000 person-years). The incidence rate ratio for mortality was 0.82 (95% CI, 0.67-1.02; P = .07) in the azithromycin group compared with the placebo group. The incidence rate ratio was 0.99 (95% CI, 0.72-1.36) in those aged 1 to 11 months, 0.92 (95% CI, 0.67-1.27) in those aged 12 to 23 months, and 0.73 (95% CI, 0.57-0.94) in those aged 24 to 59 months. Conclusions and Relevance: Mortality in children (aged 1-59 months) was lower with biannual mass azithromycin distribution in a setting in which seasonal malaria chemoprevention was also being distributed, but the difference was not statistically significant. The study may have been underpowered to detect a clinically relevant difference. Trial Registration: ClinicalTrials.gov Identifier: NCT03676764.
Assuntos
Antibacterianos , Azitromicina , Mortalidade da Criança , Malária , Humanos , Azitromicina/provisão & distribuição , Azitromicina/uso terapêutico , Burkina Faso/epidemiologia , Quimioprevenção/métodos , Quimioprevenção/estatística & dados numéricos , Mortalidade da Criança/tendências , Malária/epidemiologia , Malária/mortalidade , Malária/prevenção & controle , Antibacterianos/provisão & distribuição , Antibacterianos/uso terapêutico , Estações do Ano , Lactente , Pré-EscolarRESUMO
Introduction: Syphilis is a sexually transmitted infection caused by the bacterium Treponema pallidum. In Brazil, its incidence has increased, along with the lack of penicillin, the antibiotic of choice for congenital syphilis, from 2014 to 2017. During this period, children were treated with alternative drugs, but to date, data from the scientific literature do not recommend another antibiotic. Objective: To compare the progression, according to the established treatment, and evaluate the follow-up in health care facilities in Vila Velha (Espírito Santo) of children with congenital syphilis aged up to two years, born in Hospital Infantil e Maternidade Alzir Bernardino Alves a reference in neonatology and low-risk pregnancy in the state at the time from 2015 to 2016, when the hospital experienced a greater lack of penicillin. Methods: This is a retrospective cross-sectional observational study based on data from medical records of the hospital and other healthcare facilities in the city. We performed statistical analyses, per health district, of epidemiological and sociodemographic data, as well as those related to visits, their frequency, and clinical profile, according to the follow-up parameters proposed by the Ministry of Health at the time. Results: Medical records of 121 children were evaluated, presenting as the main findings: only 35% of the children completed the follow-up; among those treated with ceftriaxone, 55.2% completed the follow-up, and 100% of the children whose venereal disease research laboratory was greater than that of their mother at birth completed the follow-up. Of the symptomatic children at birth who remained or became symptomatic at follow-up, 58.8% used ceftriaxone. Conclusion: Among symptomatic children at birth, most of those treated with ceftriaxone remained symptomatic at follow-up. The Counseling and Testing Center was the most successful facility in the follow-up of these children. District 5 had the lowest success rate in the follow-up of these patients, and districts 1 and 2 showed the lowest rates of appropriate approach to congenital syphilis during follow-up. (AU)
Introdução: A sífilis é uma infecção sexualmente transmissível causada pela bactéria Treponema pallidum. No Brasil, sua incidência vem aumentando, acompanhada da falta de penicilina, antibiótico de escolha para a sífilis congênita, no período de 20142017. Nesse período, as crianças foram tratadas com medicamentos alternativos, porém dados da literatura científica até o momento não recomendam outro antibiótico. Objetivo: Comparar a evolução, de acordo com o tratamento instituído, e avaliar o acompanhamento nas unidades de saúde em Vila Velha (ES), até os dois anos de idade, das crianças com sífilis congênita nascidas no Hospital Infantil e Maternidade Alzir Bernardino Alves referência em neonatologia e gravidez de baixo risco no estado na época de 2015 a 2016, período em que houve maior falta de penicilina no hospital. Métodos: Estudo observacional do tipo transversal, retrospectivo, baseado em dados dos prontuários do hospital e outras Unidades de Saúde do município. Foram analisados estatisticamente, por região de saúde, dados epidemiológicos, sociodemográficos, bem como relativos às consultas, sua periodicidade e ao perfil clínico, de acordo com os parâmetros de seguimento propostos pelo Ministério da Saúde na época. Resultados: Avaliaram-se os prontuários de 121 crianças, obtendo-se como principais achados: somente 35% das crianças tiveram seguimento completo; das crianças tratadas com ceftriaxona, 55,2% tiveram seguimento completo, e 100% das crianças que tiveram VDRL maior que o da mãe no parto completaram o seguimento. Das crianças sintomáticas ao nascimento e que permaneceram ou ficaram sintomáticas no seguimento, 58,8% fizeram uso de ceftriaxona. Conclusão: Das crianças sintomáticas ao nascimento, as tratadas com ceftriaxona, em sua maioria, mantiveram-se sintomáticas no seguimento. O Centro de Testagem e Aconselhamento teve maior êxito no acompanhamento dessas crianças. A região 5 teve a menor taxa de êxito no seguimento desses pacientes, e as regiões 1 e 2 menor taxa de abordagem correta para sífilis congênita durante o seguimento. (AU)
Assuntos
Humanos , Feminino , Criança , Adulto , Penicilinas/provisão & distribuição , Sífilis Congênita/tratamento farmacológico , Antibacterianos/provisão & distribuição , Penicilinas/uso terapêutico , Estudos Transversais , Estudos Retrospectivos , Seguimentos , Antibacterianos/uso terapêuticoRESUMO
STUDY DESIGN: Retrospective study using prospectively collected data. OBJECTIVE: This study aimed to investigate the effect of alternative antimicrobial prophylaxis agents on surgical site infections (SSIs) after spine surgery. SUMMARY OF BACKGROUND DATA: Although the use of alternative antimicrobial prophylaxis agents might have a negative effect on SSI prevention, their association with SSI risk in spine surgery remains unclear. METHODS: We used the registry data of consecutive patients undergoing spine surgery from April 2017 to January 2020 in four institutions participating in the University of Tokyo Spine Group. Before March 2019, all institutions used cefazolin for antimicrobial prophylaxis. After March 2019, the institutions used broad-spectrum beta-lactam agents as an alternative due to a cefazolin shortage in Japan. RESULTS: Among the 3841 enrolled patients (2289 males), 2024 received cefazolin and 1117 received alternative agents. The risk of reoperation for deep SSI within 30âdays of spine surgery was significantly higher in the alternative antimicrobial prophylaxis agent group (adjusted odds ratio [aOR] 1.96; 95% confidence interval [CI], 1.15-3.35; Pâ=â0.014). In subgroup analyses, the SSI risk was significantly higher in the thoracolumbar surgery group (aOR 1.98; 95% CI, 1.06-3.73; Pâ=â0.03). A nonsignificant consistent trend was found in all other subgroups: posterior decompression (aOR 1.91; 95% CI, 0.86-4.21; Pâ=â0.11); posterior fixation (aOR 2.05; 95% CI, 0.99-4.24; Pâ=â0.05); and cervical spine surgery (aOR 2.30; 95% CI, 0.82-6.46; Pâ=â0.11). CONCLUSION: Alternative antimicrobial prophylaxis agents increased the risk of reoperation for SSI after spine surgery compared with cefazolin. Our study supports the current practice of using first-generation cephalosporins as first-line antimicrobial prophylaxis agents in spine surgery as recommended in multiple guidelines.Level of Evidence: 3.
Assuntos
Antibacterianos/provisão & distribuição , Cefazolina/provisão & distribuição , Coluna Vertebral/cirurgia , Infecção da Ferida Cirúrgica , Antibacterianos/uso terapêutico , Antibioticoprofilaxia/estatística & dados numéricos , Cefazolina/uso terapêutico , Humanos , Japão , Reoperação/estatística & dados numéricos , Estudos Retrospectivos , Infecção da Ferida Cirúrgica/tratamento farmacológico , Infecção da Ferida Cirúrgica/epidemiologiaRESUMO
BACKGROUND: Drug shortages may negatively impact outcomes in hospitalized patients. A cefepime dosing regimen of 1 gram every 6 hours (1 g q6h) has shown to provide similar exposures above target minimum inhibitory concentrations compared to the regimen of 2 g q8h approved by the United States Food and Drug Administration (FDA) for febrile neutropenia. Our objective was to determine if the dosing regimen of 1 g q6h amidst a cefepime shortage is an appropriate alternative for the treatment of febrile neutropenia. METHODS: A retrospective chart review of hospitalized patients who received cefepime for febrile neutropenia over a two-year period was performed. Patients were grouped based on cefepime dosing strategy: 2 g q8h vs. 1 g q6h. The primary objective was to compare time to defervescence after cefepime initiation. Secondary objectives included all-cause 30-day mortality, duration of antibiotic therapy, and inpatient length of stay. RESULTS: Seventy-five patients in each arm were included. There were no differences in baseline age or severity of illness between groups. There was no difference in the primary objective as median time to defervescence was similar between the 2 g q8h and 1 g q6h groups (69.0 vs. 65.3 h: p= 0.67). Additionally, no differences were found in the secondary objectives of all-cause 30-day mortality (10.7% vs. 9.3%: p = 0.79), duration of therapy (80.8 vs. 88.0 h: p = 0.34), or length of stay (9 vs. 7 days: p = 0.50). CONCLUSIONS: Our study identified no differences in clinical outcomes with cefepime 1 g q6h compared to the traditional FDA-approved 2 g q8h regimen for the treatment of febrile neutropenia.
Assuntos
Antibacterianos/administração & dosagem , Cefepima/administração & dosagem , Neutropenia Febril/tratamento farmacológico , Idoso , Antibacterianos/provisão & distribuição , Cefepima/provisão & distribuição , Esquema de Medicação , Feminino , Humanos , Tempo de Internação , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Mortalidade , Estudos Retrospectivos , Fatores de TempoRESUMO
OBJECTIVES: Our aims were to examine AMR-specific and AMR-sensitive factors associated with antibiotic consumption in Nepal between 2006 and 2016, to explore health care-seeking patterns and the source of antibiotics. METHODS: Cross-sectional data from children under five in households in Nepal were extracted from the 2006, 2011 and 2016 Demographic Health Surveys (DHS). Bivariable and multivariable analyses were carried out to assess the association of disease prevalence and antibiotic use with age, sex, ecological location, urban/rural location, wealth index, household size, maternal smoking, use of clean fuel, sanitation, nutritional status, access to health care and vaccinations. RESULTS: Prevalence of fever, acute respiratory infection (ARI) and diarrhoea decreased between 2006 and 2016, whilst the proportion of children under five receiving antibiotics increased. Measles vaccination, basic vaccinations, nutritional status, sanitation and access to health care were associated with antibiotic use. Those in the highest wealth index use less antibiotics and antibiotic consumption in rural areas surpassed urban regions over time. Health seeking from the private sector has overtaken government facilities since 2006 with antibiotics mainly originating from pharmacies and private hospitals. Adherence to WHO-recommended antibiotics has fallen over time. CONCLUSIONS: With rising wealth, there has been a decline in disease prevalence but an increase in antibiotic use and more access to unregulated sources. Understanding factors associated with antibiotic use will help to inform interventions to reduce inappropriate antibiotic use whilst ensuring access to those who need them.
Assuntos
Antibacterianos/uso terapêutico , Saúde da Criança , Atenção à Saúde/tendências , Diarreia/tratamento farmacológico , Febre/tratamento farmacológico , Aceitação pelo Paciente de Cuidados de Saúde , Infecções Respiratórias/tratamento farmacológico , Antibacterianos/provisão & distribuição , Pré-Escolar , Estudos Transversais , Diarreia/epidemiologia , Farmacorresistência Bacteriana , Características da Família , Febre/epidemiologia , Fidelidade a Diretrizes/tendências , Instalações de Saúde , Inquéritos Epidemiológicos , Humanos , Lactente , Masculino , Nepal , Pediatria , Prevalência , Setor Privado , Infecções Respiratórias/epidemiologia , População Rural , Saneamento , Classe SocialRESUMO
OBJECTIVE: To obtain the perspectives of some small- and medium-sized organizations on the World Health Organization (WHO) prequalification programme for medicines and to ascertain organizations' unmet needs. METHODS: We conducted an exploratory, qualitative study in 2018 among 17 representatives of 15 small- and medium-sized Belgian and non-Belgian organizations who purchase medicines for humanitarian, development or public programmes in low- and middle-income countries. We used semi-structured interviews to obtain respondents' views and experiences of using WHO prequalification guidance when procuring medicines. We identified emerging themes and formulated recommendations about the activities of the WHO Prequalification Team. FINDINGS: Most respondents suggested expanding prequalification to essential antibiotics, particularly paediatric formulations; and insulin, antihypertensives and cancer treatments. Respondents were concerned about irregular availability of WHO-prequalified medicines in the marketplace and sometimes high prices of prequalified products. Small organizations, in particular, had difficulties negotiating low-volume purchases. Organizations working in primary health care and hospitals seldom referred to the prequalified lists. CONCLUSION: We recommend that the WHO-prequalified products be expanded to include essential antibiotics and medicines for noncommunicable diseases. The WHO Prequalification Team could require prequalified manufacturers to make publicly available the details of their authorized distributors and facilitate a process of harmonization of quality assurance policies across all donors. Prequalification of distributors and procurement agencies could help create more transparent and stringent mechanisms. We urge WHO Member States and funders to sustain support for the WHO Prequalification Team, which remains important for the fulfilment of universal health coverage.
Assuntos
Medicamentos Essenciais/provisão & distribuição , Saúde Global , Organizações/organização & administração , Medicamentos sob Prescrição/provisão & distribuição , Organização Mundial da Saúde/organização & administração , Antibacterianos/provisão & distribuição , Humanos , Doenças não Transmissíveis/tratamento farmacológico , Organizações/normas , Pesquisa QualitativaAssuntos
Pesquisa Biomédica/economia , Poluição Ambiental/prevenção & controle , Aquecimento Global/prevenção & controle , Lua , Neoplasias/prevenção & controle , Plásticos/isolamento & purificação , Voo Espacial , Antibacterianos/provisão & distribuição , Comportamento Cooperativo , Poluição Ambiental/economia , Aquecimento Global/economia , Humanos , Neoplasias/economia , Neoplasias/terapia , Política , Voo Espacial/economiaRESUMO
This cross-sectional study was carried out to assess drug prescribing pattern at a tertiary care teaching medical institute. One thousand prescriptions were randomly collected and analyzed using the world health organization prescribing indicators. The average number of drugs per prescription was 2.91. The percentage of drugs prescribed by generic name, from the essential drug list (National) and as fixed dose combinations (FDCs) was 10.05%, 22.57%, and 49.22%, respectively. The total percentage of encounters with antibiotics, injectables, and FDCs was 19.70%, 2.20%, and 73.60%, respectively. The most common group of drug prescribed was gastrointestinal tract drugs (26.38%) followed by Vitamins and Minerals (23.12%), cardiovascular system drugs (11.56%) and antimicrobials (9.63%). The prescribing practices were not appropriate as they consist of polypharmacy, lesser prescription by generic name, and overprescription of FDCs. There is a need for improvement in the standards of prescribing patterns in many aspects.
Assuntos
Prescrições de Medicamentos/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Antibacterianos/provisão & distribuição , Estudos Transversais , Uso de Medicamentos/estatística & dados numéricos , Medicamentos Essenciais/provisão & distribuição , Medicamentos Genéricos/provisão & distribuição , Hospitais de Ensino/estatística & dados numéricos , Humanos , Índia , Injeções/estatística & dados numéricos , Centros de Atenção Terciária/estatística & dados numéricos , Organização Mundial da SaúdeRESUMO
While medical historians have paid ample attention to the introduction of antibiotics and their impact on hospital-based practice during and after the Second World War, the multiple issues surrounding their use in Scottish hospitalsare sorely lacking in current discussions. Drawing on an extensive yet underused range of materials including patient treatment records, oral histories and medical correspondence, this paper explores the introduction of penicillin for civilian treatment at the Royal Infirmary of Edinburgh during the closing stages of the War. It highlights the success of the drug in clinical treatment as well as its shortcomings, offering an alternative view of its initial impact on surgical practice.
Assuntos
Antibacterianos/história , Resistência Microbiana a Medicamentos , Hospitais/história , Controle de Infecções/história , Penicilinas/história , Guerra , II Guerra Mundial , Antibacterianos/provisão & distribuição , Antibacterianos/uso terapêutico , Cirurgia Geral/história , História do Século XX , Humanos , Controle de Infecções/métodos , Penicilinas/provisão & distribuição , Penicilinas/uso terapêutico , EscóciaRESUMO
Rheumatic heart disease (RHD) is a chronic valvular disease resulting after severe or repetitive episodes of acute rheumatic fever (ARF), an autoimmune response to group A Streptococcus infection. RHD has been almost eliminated with improved social and health infrastructure in affluent countries while it remains a neglected disease with major cause of morbidity and mortality in many low- and middle-income countries, and resource-limited regions of high-income countries. Despite our evolving understanding of the pathogenesis of RHD, there have not been any significant advances to prevent or halt progression of disease in recent history. Long-term penicillin-based treatment and surgery remain the backbone of a RHD control program in the absence of an effective vaccine. The advent of echocardiographic screening algorithms has improved the accuracy of diagnosing RHD and has shed light on the enormous burden of disease. Encouragingly, this has led to a rekindled commitment from researchers in the most affected countries to advocate and take bold actions to end this disease of social inequality.
Assuntos
Antibacterianos/uso terapêutico , Procedimentos Cirúrgicos Cardíacos/estatística & dados numéricos , Penicilina G Benzatina/uso terapêutico , Prevenção Primária/organização & administração , Cardiopatia Reumática/prevenção & controle , Prevenção Secundária/organização & administração , Streptococcus pyogenes/patogenicidade , Antibacterianos/provisão & distribuição , Países em Desenvolvimento , Progressão da Doença , Fidelidade a Diretrizes , Prioridades em Saúde , Necessidades e Demandas de Serviços de Saúde , Humanos , Doenças Negligenciadas , Penicilina G Benzatina/provisão & distribuição , Guias de Prática Clínica como Assunto , Melhoria de Qualidade , Cardiopatia Reumática/diagnóstico , Cardiopatia Reumática/epidemiologiaRESUMO
The aim of this study was to investigate the antibacterial resistance of Streptococcus pyogenes (GAS), and correlate the findings with the sales of erythromycin and tetracycline. General practitioners in the Faroe Islands were recruited to send oropharyngeal swabs. From an ongoing pneumococcal study, nasopharyngeal swabs were sampled from healthy children 0-7 years of age. Erythromycin susceptibility data from Iceland were obtained from the reference laboratory at the Landspitali University Hospital. Susceptibility testing in the Faroe Islands and Iceland was performed according to CLSI methods and criteria. The resistance rate to erythromycin and tetracycline found in patients in the Faroe Islands in 2009/2010 was 6% and 30% respectively. Tetracycline resistance in patients declined significantly from 2009 to 2010 (37-10%, p-value = 0.006 < 0.05) and differed significantly between age groups (p-value = 0.03 < 0.05). In Iceland, there was a peak in erythromycin resistance in 2008 (44%) and a substantial decrease in 2009 (5%). Although the prevalence of erythromycin and tetracycline resistance in the Faroe Islands and Iceland may be associated with antimicrobial use, sudden changes can occur with the introduction of new resistant clones.
Assuntos
Antibacterianos/provisão & distribuição , Farmacorresistência Bacteriana , Eritromicina/provisão & distribuição , Streptococcus pyogenes/efeitos dos fármacos , Tetraciclina/provisão & distribuição , Tonsilite/tratamento farmacológico , Adolescente , Adulto , Idoso , Antibacterianos/economia , Antibacterianos/farmacologia , Doenças Assintomáticas , Criança , Pré-Escolar , Dinamarca/epidemiologia , Eritromicina/economia , Eritromicina/farmacologia , Feminino , Humanos , Islândia/epidemiologia , Lactente , Recém-Nascido , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Orofaringe/efeitos dos fármacos , Orofaringe/microbiologia , Infecções Estreptocócicas/epidemiologia , Infecções Estreptocócicas/microbiologia , Streptococcus pyogenes/crescimento & desenvolvimento , Streptococcus pyogenes/isolamento & purificação , Tetraciclina/economia , Tetraciclina/farmacologia , Tonsilite/epidemiologia , Tonsilite/microbiologiaRESUMO
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain major causes of heart failure, stroke and death among African women and children, despite being preventable and imminently treatable. From 21 to 22 February 2015, the Social Cluster of the Africa Union Commission (AUC) hosted a consultation with RHD experts convened by the Pan-African Society of Cardiology (PASCAR) in Addis Ababa, Ethiopia, to develop a 'roadmap' of key actions that need to be taken by governments to eliminate ARF and eradicate RHD in Africa. Seven priority areas for action were adopted: (1) create prospective disease registers at sentinel sites in affected countries to measure disease burden and track progress towards the reduction of mortality by 25% by the year 2025, (2) ensure an adequate supply of high-quality benzathine penicillin for the primary and secondary prevention of ARF/RHD, (3) improve access to reproductive health services for women with RHD and other non-communicable diseases (NCD), (4) decentralise technical expertise and technology for diagnosing and managing ARF and RHD (including ultrasound of the heart), (5) establish national and regional centres of excellence for essential cardiac surgery for the treatment of affected patients and training of cardiovascular practitioners of the future, (6) initiate national multi-sectoral RHD programmes within NCD control programmes of affected countries, and (7) foster international partnerships with multinational organisations for resource mobilisation, monitoring and evaluation of the programme to end RHD in Africa. This Addis Ababa communiqué has since been endorsed by African Union heads of state, and plans are underway to implement the roadmap in order to end ARF and RHD in Africa in our lifetime.
Assuntos
Prestação Integrada de Cuidados de Saúde/organização & administração , Prioridades em Saúde/organização & administração , Necessidades e Demandas de Serviços de Saúde/organização & administração , Avaliação das Necessidades/organização & administração , Prevenção Primária/organização & administração , Febre Reumática/prevenção & controle , Cardiopatia Reumática/prevenção & controle , Prevenção Secundária/organização & administração , África/epidemiologia , Antibacterianos/provisão & distribuição , Procedimentos Cirúrgicos Cardíacos , Comportamento Cooperativo , Acessibilidade aos Serviços de Saúde/organização & administração , Humanos , Cooperação Internacional , Penicilina G Benzatina/provisão & distribuição , Sistema de Registros , Febre Reumática/diagnóstico , Febre Reumática/epidemiologia , Cardiopatia Reumática/diagnóstico , Cardiopatia Reumática/epidemiologiaRESUMO
BACKGROUND: Neomycin contact sensitization rates in North America range from 7% to 13%, whereas in Europe they average approximately 1.9%. OBJECTIVES: Given that topical neomycin products are no longer readily available in Canada, the aim of this study was to examine what influence this may have had on neomycin sensitization rates in the 3 western provinces. METHODS: On the basis of an observation originally communicated by L. M. Parsons and C. Zhang of the University of Calgary, which suggested significantly reduced rates of neomycin sensitization in Calgary, Alberta, Canada, a multicenter study of patch test results from 5690 patient charts was undertaken. Data from 3 other western Canadian Universities (the University of Saskatchewan, the University of Alberta, and the University of British Colombia) were analyzed. Data were available from 2001 to 2013 for the University of Saskatchewan (except 2006), whereas the University of Alberta and the University of British Columbia had data from 2009 to 2013. Descriptive statistics, trend analysis, and risk estimates were determined using SPSS version 20. RESULTS: Sensitization rates for neomycin have decreased in western Canada and are now similar to those of Europe. CONCLUSIONS: This trend is likely influenced by the reduced availability of over-the-counter and prescription neomycin products in Canada.
Assuntos
Antibacterianos/efeitos adversos , Dermatite Alérgica de Contato/epidemiologia , Dermatite Alérgica de Contato/etiologia , Toxidermias/epidemiologia , Toxidermias/etiologia , Neomicina/efeitos adversos , Alberta/epidemiologia , Antibacterianos/provisão & distribuição , Colúmbia Britânica/epidemiologia , Europa (Continente)/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neomicina/provisão & distribuição , Testes do Emplastro , Prevalência , Saskatchewan/epidemiologiaRESUMO
Ceftazidime is the only anti-pseudomonal beta-lactam that has been reported to be administered by extended infusion in pediatric cystic fibrosis (CF) patients. A small pediatric pharmacokinetic/pharmacodynamic study has been published regarding the use of intermittent extended infusion doripenem in the treatment of an acute pulmonary exacerbation (APE) in pediatric CF patients; however, clinical use of intermittent extended infusion doripenem in pediatric CF patients has not been previously reported. We present three cases administering intermittent extended infusion doripenem in pediatric CF patients for the treatment of an APE in the case of replacing meropenem due to shortage. The delivery of beta-lactam antibiotics via intermittent extended infusion should be considered in order to optimize the pharmacodynamics of beta-lactams in the treatment of an APE.
Assuntos
Antibacterianos/uso terapêutico , Infecções por Burkholderia/tratamento farmacológico , Carbapenêmicos/uso terapêutico , Fibrose Cística/tratamento farmacológico , Infecções por Pseudomonas/tratamento farmacológico , Adolescente , Antibacterianos/provisão & distribuição , Infecções por Burkholderia/complicações , Burkholderia cenocepacia/isolamento & purificação , Criança , Fibrose Cística/complicações , Fibrose Cística/microbiologia , Progressão da Doença , Doripenem , Quimioterapia Combinada , Feminino , Infecções por Bactérias Gram-Negativas/complicações , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Humanos , Infusões Intravenosas , Meropeném , Infecções por Pseudomonas/complicações , Pseudomonas aeruginosa/isolamento & purificação , Pseudomonas stutzeri/isolamento & purificação , Rhodospirillaceae/isolamento & purificação , Tienamicinas/provisão & distribuição , Tobramicina/uso terapêutico , Resultado do Tratamento , Combinação Trimetoprima e Sulfametoxazol/uso terapêuticoRESUMO
PROBLEMA: ¿Cuál es la percepción sobre la automedicación con antibióticos en los usuarios de consultorio externo del Hospital Nacional Arzobispo Loayza? Hipótesis: Existe relación directa entre el grado de instrucción y la automedicación con antibióticos en los sujetos de estudio. Objetivo: Identificar las percepciones más comunes sobre la automedicación con antibióticos en los usuarios de consultorio externo del HNAL. MATERIAL Y METODOS: Estudio tipo encuesta, de carácter prospectivo observacional, descriptivo y transversal. Población: Usuarios de Consultorios Externos del Hospital Nacional Arzobispo Loayza, Lima Perú, a partir del mes de Noviembre del año 2011 en adelante. Muestra: n=369. RESULTADOS: El 58 por ciento de los usuarios se auto medican con antibióticos, el grado de instrucción superior es menos prevalente en quienes se auto medican (38 por ciento) comparado con quienes no practican esta actividad (53,8 por ciento), (p=0,003). Los síntomas respiratorios fueron la causa más común para la automedicación y el 84,5 por ciento consideran a los antibióticos en el tratamiento del resfrío común. También perciben motivos no relacionados al estado de la salud para automedicarse, como tratamiento "Ya conocido", "Confianza en el personal de la farmacia" o "tiempo prolongado de espera en el hospital previo a la consulta médica". Los antibióticos más usados en la automedicación son los Betalactámicos, Quinolonas y Aminoglucósidos. Durante la automedicación, el 49,3 por ciento acceden a los antibióticos por petición directa y el 33,3 por ciento por sugerencia del personal de la farmacia. Durante el consumo de antibióticos sin receta médica, el 89,2 por ciento consideran "mejoría de sus síntomas". CONCLUSIONES: El 58 por ciento de los usuarios de consultorio externo del HNAL practica la automedicación con antibióticos, siendo probablemente las infecciones respiratorias, la causa más común, sin embargo se describen otras causas no relacionados al estado de salud...
PROBLEM: What is the perception of self-medication with antibiotics in outpatient users Hospital Nacional Arzobispo Loayza?. HYPOTHESIS: There is a direct relationship between the level of education and self- medication with antibiotics in the study subjects. Objective: To identify more usual perceptions on self medication with antibiotics in outpatient users the HNAL. MATERIAL AND METHODS: Interview-study. A prospective, observational, descriptive and transversal. Population: External Doctor users Hospital Nacional Arzobispo Loayza, Lima Peru, from the month of November, 2011 onwards. Sample: n=369. RESULTS: 58 per cent of users did self medicate with antibiotics, higher educational attainment is less prevalent in those who selfmedicate (38 per cent) compared to those who do not practice this activity (53.8 per cent), (p=0.003). Respiratory symptoms were the most common cause for self-medication and 84.5 per cent considered to antibiotics in the treatment of the common cold. Also reasons related to perceived health status to self-medicate, as treatment "already known", "Trust in the pharmacy staff" or "long time waiting in the hospital before medical consultation." The antibiotics used in self-medication are the beta-lactams, quinolones and aminoglycosides. During the self-medication, 49.3 per cent use direct request antibiotics and 33.3 per cent at the suggestion of pharmacy staff. During the consumption of antibiotics without prescription, 89.2 per cent consider "improvement in their symptoms". CONCLUSIONS: The 58 per cent of outpatient users of HNAL practiced self-medication with antibiotics, respiratory infections being probably the most common cause, however described other causes unrelated to health status as "therapy known as", "confidence in the pharmacy staff" or "prolonged delay before medical consultation" as possible causes of self-medication. Antibiotics groups used for this practice were the beta-lactams, quinolones and aminoglycosides.
Assuntos
Humanos , Masculino , Adulto , Feminino , Adulto Jovem , Pessoa de Meia-Idade , Antibacterianos/provisão & distribuição , Automedicação , Uso de Medicamentos , Estudo Observacional , Estudos Prospectivos , Estudos TransversaisAssuntos
Antineoplásicos/provisão & distribuição , Indústria Farmacêutica/legislação & jurisprudência , Medicamentos Genéricos/provisão & distribuição , Antibacterianos/provisão & distribuição , Medicamentos Genéricos/economia , Regulamentação Governamental , Humanos , Injeções , Estados Unidos , United States Food and Drug AdministrationAssuntos
Antibacterianos/provisão & distribuição , Infecções Bacterianas/tratamento farmacológico , Farmacorresistência Bacteriana , Promoção da Saúde/organização & administração , Nível de Saúde , Medicamentos sob Prescrição/provisão & distribuição , Antibacterianos/economia , Antibacterianos/uso terapêutico , Infecções Bacterianas/epidemiologia , Custos de Medicamentos/estatística & dados numéricos , Humanos , Programas Nacionais de Saúde/organização & administração , Medicamentos sob Prescrição/economia , Medicamentos sob Prescrição/uso terapêutico , África do SulRESUMO
Background: The Chilean Ministry of Health has implemented regulatory rules for the consumption of anti-biotics since September 1999, with sales restriction limited only with medical prescription. Aim: To analyze the impact of established regulatory measures from 2000 to 2008. Material and Methods: A retrospective analysis of antibiotics sales in pharmacies from 2000 to 2008 was performed. The information was obtained from the International Marketing System (IMS Health), an auditing system of pharmacy sales. The consumption unit used was the Defined Daily Dose per 1000 inhabitants/day (DDD). Results: From 2000 to 2002 the regulatory rules had a great impact, but since 2002 the antibiotic consumption increased, especially amoxicillin, returning to similar levéis observed in 1998. Conclusions: The regulatory measures had an initial impact, but there was not reinforcement in the time and there was no further control. It is necessary to assume a permanent task and support of the authorities of health to edúcate the population about the implications of the inadequate use of antimicrobials and his effect on the microbial ecology.
Introducción: El Ministerio de Salud de Chile reguló el consumo de antimicrobianos en el mes de septiembre de 1999, mediante restricción de venta limitada sólo a venta con receta médica. El objetivo de este estudio es conocer el impacto de las medidas regulatorias entre los años 2000 y 2008. Metodología: Se realizó un análisis retrospectivo de las ventas en farmacias privadas desde el año 2000 al 2008. La información se obtuvo del International Marketing System Health (IMS Health), una empresa internacional encargada de auditar las ventas de farmacias. La unidad de consumo usada fue la DDD/1.000 habitantes-día. Resultados: A partir del año 2000 al 2002, las medidas regulatorias tuvieron un gran impacto; sin embargo, desde el año 2002 el consumo de antimicrobianos aumentó, especialmente amoxicilina, obteniéndose valores similares a los existentes en 1998. Conclusiones: Las medidas regulatorias tuvieron un impacto inicial; sin embargo, no fueron reforzadas ni controladas en el tiempo. Es necesario que las autoridades de salud del país asuman la tarea pennanente de educar a la comunidad acerca del uso inadecuado de antimicrobianos y su efecto sobre la ecología bacteriana.
Assuntos
Humanos , Antibacterianos , Legislação de Medicamentos , Farmácias/estatística & dados numéricos , Antibacterianos/provisão & distribuição , Chile , Uso de Medicamentos/legislação & jurisprudência , Uso de Medicamentos/estatística & dados numéricos , Farmácias/legislação & jurisprudência , Estudos RetrospectivosRESUMO
BACKGROUND: Variation in medical practice has identified opportunities for quality improvement in patient care. The degree of variation in the use of antibiotics in children's hospitals is unknown. METHODS: We conducted a retrospective cohort study of 556,692 consecutive pediatric inpatient discharges from 40 freestanding children's hospitals between January 1, 2008, and December 31, 2008. We used the Pediatric Health Information System to acquire data on antibiotic use and clinical diagnoses. RESULTS: Overall, 60% of the children received at least 1 antibiotic agent during their hospitalization, including >90% of patients who had surgery, underwent central venous catheter placement, had prolonged ventilation, or remained in the hospital for >14 days. Even after adjustment for both hospital- and patient-level demographic and clinical characteristics, antibiotic use varied substantially across hospitals, including both the proportion of children exposed to antibiotics (38%-72%) and the number of days children received antibiotics (368-601 antibiotic-days per 1000 patient-days). In general, hospitals that used more antibiotics also used a higher proportion of broad-spectrum antibiotics. CONCLUSIONS: Children's hospitals vary substantially in their use of antibiotics to a degree unexplained by patient- or hospital-level factors typically associated with the need for antibiotic therapy, which reveals an opportunity to improve the use of these drugs.
Assuntos
Antibacterianos/provisão & distribuição , Fidelidade a Diretrizes , Hospitais Pediátricos/estatística & dados numéricos , Padrões de Prática Médica , Melhoria de Qualidade , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Estudos Retrospectivos , Estados UnidosRESUMO
OBJECTIVE: The objective of this study has been to examine antibiotic consumption in Spain through the use of the National Surveys of Health (NSH) . MATERIAL AND METHODS: Taking the NSH, between 1993 and 2003, certain variables regarding the consumption of antibiotics have been analyzed; putting these into groups according to their typology, habits, comorbidity and the utilization of health resources. This information has been compared with published data by other authors. RESULTS: The consumption of antibiotics was approximately 3%, and 9-19% of this was not prescribed. Significant statistical associations have been observed between the consumption of antibiotics and other aspects such as academic and income levels, habits such as smoking, general health, certain chronic diseases, being bed-ridden due to disease; and also the use of certain medicines and the anti-influenza vaccine. CONCLUSIONS: Consumption of antibiotics coincides with described data by other authors, and this was always higher than prescribed. The association with other variables may be limited by the inadequate NSH design in order to know the exact consumption of antibiotics.